Literature DB >> 1847977

Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients.

T Le Chevalier1, R Arriagada, E Quoix, P Ruffie, M Martin, M Tarayre, M J Lacombe-Terrier, J Y Douillard, A Laplanche.   

Abstract

We report the results observed in a large, randomized study that compared the effects of radiotherapy alone (the standard therapy) with those of a combination of radiotherapy and chemotherapy in nonresectable squamous cell and large-cell lung carcinoma. The radiation dose was 65 Gy in each group, and chemotherapy included vindesine, cyclophosphamide, cisplatin, and lomustine. In this study, 177 patients received radiotherapy alone (group A), and 176 patients received the combined treatment (group B). The 2-year survival rate was 14% in group A and 21% in group B (P = .08). The distant metastasis rate was significantly lower in group B (P less than .001). Local control was poor in both groups (17% and 15%, respectively) and remained the major problem.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1847977     DOI: 10.1093/jnci/83.6.417

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  98 in total

1.  p53 Gene therapy for lung cancer.

Authors:  Stephen G Swisher; Jack A Roth
Journal:  Curr Oncol Rep       Date:  2002-07       Impact factor: 5.075

Review 2.  Locally advanced non-small cell lung cancer.

Authors:  E E Cohen; E E Vokes
Journal:  Curr Treat Options Oncol       Date:  2001-02

Review 3.  Lung cancer.

Authors:  R Souhami
Journal:  BMJ       Date:  1992-05-16

Review 4.  Hyperfractionated and accelerated radiotherapy in non-small cell lung cancer.

Authors:  Kate Haslett; Christoph Pöttgen; Martin Stuschke; Corinne Faivre-Finn
Journal:  J Thorac Dis       Date:  2014-04       Impact factor: 2.895

5.  Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non-Small Cell Lung Cancer: NCCTG N0028 (Alliance).

Authors:  Steven E Schild; Shauna L Hillman; Angelina D Tan; Helen J Ross; William L McGinnis; Yolanda A Garces; David L Graham; Alex A Adjei; James R Jett
Journal:  J Thorac Oncol       Date:  2017-01-12       Impact factor: 15.609

6.  Signaling pathways in NSCLC as a predictor of outcome and response to therapy.

Authors:  Anjali K Gupta; Daniel E Soto; Michael D Feldman; Jeffrey D Goldsmith; Rosemarie Mick; Stephen M Hahn; Mitchell Machtay; Ruth J Muschel; W Gillies McKenna
Journal:  Lung       Date:  2004       Impact factor: 2.584

7.  Concurrent low-dose cisplatin and thoracic radiotherapy in patients with inoperable stage III non-small cell lung cancer: a phase II trial with special reference to the hemoglobin level as prognostic parameter.

Authors:  O Pradier; K Lederer; A Hille; E Weiss; H Christiansen; H Schmidberger; C F Hess
Journal:  J Cancer Res Clin Oncol       Date:  2004-12-23       Impact factor: 4.553

8.  Dose escalation for unresectable locally advanced non-small cell lung cancer: end of the line?

Authors:  Julian C Hong; Joseph K Salama
Journal:  Transl Lung Cancer Res       Date:  2016-02

9.  Treatment outcomes of three-dimensional conformal radiotherapy for stage III non-small cell lung cancer.

Authors:  Seung-Gu Yeo; Moon-June Cho; Sun-Young Kim; Seung-Pyung Lim; Ki-Hwan Kim; Jun-Sang Kim
Journal:  Cancer Res Treat       Date:  2005-10-31       Impact factor: 4.679

10.  Outcome and toxicity profiles in the treatment of locally advanced lung cancer with volumetric modulated arc therapy.

Authors:  Marta Scorsetti; Piera Navarria; Fiorenza De Rose; AnnaMaria Ascolese; Elena Clerici; Ciro Franzese; Francesca Lobefalo; Giacomo Reggiori; Pietro Mancosu; Stefano Tomatis; Antonella Fogliata; Luca Cozzi
Journal:  J Cancer Res Clin Oncol       Date:  2014-06-17       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.